JPWO2022220227A1 - - Google Patents

Info

Publication number
JPWO2022220227A1
JPWO2022220227A1 JP2023514646A JP2023514646A JPWO2022220227A1 JP WO2022220227 A1 JPWO2022220227 A1 JP WO2022220227A1 JP 2023514646 A JP2023514646 A JP 2023514646A JP 2023514646 A JP2023514646 A JP 2023514646A JP WO2022220227 A1 JPWO2022220227 A1 JP WO2022220227A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514646A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022220227A1 publication Critical patent/JPWO2022220227A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
JP2023514646A 2021-04-14 2022-04-12 Pending JPWO2022220227A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021068414 2021-04-14
PCT/JP2022/017548 WO2022220227A1 (ja) 2021-04-14 2022-04-12 テトラヒドロピリドピリミジン化合物

Publications (1)

Publication Number Publication Date
JPWO2022220227A1 true JPWO2022220227A1 (pl) 2022-10-20

Family

ID=83640095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514646A Pending JPWO2022220227A1 (pl) 2021-04-14 2022-04-12

Country Status (3)

Country Link
JP (1) JPWO2022220227A1 (pl)
TW (1) TW202304908A (pl)
WO (1) WO2022220227A1 (pl)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078010B1 (en) * 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
US8349838B2 (en) * 2008-07-09 2013-01-08 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
SG172997A1 (en) * 2009-01-16 2011-08-29 Rigel Pharmaceuticals Inc Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
PL2693881T3 (pl) * 2011-04-01 2020-03-31 University Of Utah Research Foundation Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL
ES2614824T3 (es) * 2011-11-14 2017-06-02 Ignyta, Inc. Derivados de uracil como inhibidores de la quinasa axl y c-met
DK2810937T3 (en) * 2012-01-31 2017-03-13 Daiichi Sankyo Co Ltd PYRIDONE DERIVATIVES
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
BR112016017897A8 (pt) * 2014-02-04 2020-06-30 Astellas Pharma Inc uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação
TWI723572B (zh) * 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
JP6621477B2 (ja) * 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用

Also Published As

Publication number Publication date
WO2022220227A1 (ja) 2022-10-20
TW202304908A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112021014123A2 (pl)
BR112023012656A2 (pl)
JPWO2022080413A1 (pl)
BR112022024743A2 (pl)
BR112022009896A2 (pl)
BR102021007058A2 (pl)
BR102020022030A2 (pl)
BR112023016292A2 (pl)
BR112023004146A2 (pl)
BR112023011610A2 (pl)
BR112023011539A2 (pl)
BR112023008976A2 (pl)
BR112023009656A2 (pl)
BR112023006729A2 (pl)
BR102021020147A2 (pl)
BR102021018926A2 (pl)
BR102021018859A2 (pl)
BR102021018167A2 (pl)
BR102021017576A2 (pl)
BR102021016837A2 (pl)
BR102021016551A2 (pl)
BR102021016375A2 (pl)
BR102021016200A2 (pl)
BR102021016176A2 (pl)
BR102021015566A2 (pl)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230517